Market Overview:
The global dengue vaccine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of dengue fever, rising awareness about dengue vaccines, and government initiatives for immunization programs. The global dengue vaccine market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into CYD-TDV, DENVax or TAK-003, TetraVax-DV,, TDENPIV V180,, and DNA vaccines. CYD-TDV is currently available in more than 50 countries across Latin America,, Europe Asia Pacific ,and Middle East & Africa .DENVAX or TAK003 has been licensed by Brazil’s Butantan Institute and it will be launched in 2019. TetraVaX - DV has completed Phase III clinical trials while TDENPIV V180 has completed Phase II clinical trials .On the basis of application,.
Product Definition:
A vaccine is a preparation of dead or weakened viruses, bacteria, or other organisms used to prevent or lessen the severity of an infection. A dengue vaccine is a vaccine that helps protect you from getting dengue fever.
CYD-TDV:
CYD-TDV (Cytomegalovirus and Togavirus Diptheria Vaccine) is a new dengue vaccine developed by the Serum Institute of India. It's a single dose non-replacement product intended for adults 18 years and above. The prime objective of this vaccine is to provide protection against severe dengue disease, which usually occurs in people over the age of 50 years.
DENVax or TAK-003:
DENVax or TAK-003 is a vaccine developed by Takara Bio Inc. for prevention against dengue virus. DENVax is the only vaccine that has been approved by the Food and Drug Administration (FDA) for preventing dengue fever and dengue hemorrhagic fever in 2015. It was granted breakthrough therapy approval from U.S FDA which was declined by the European Union's Committee for Medicinal Products for Human Use (CHMP).
Application Insights:
The government institutions application segment accounted for the largest share of over 50% in 2017. The rising number of dengue cases across the globe has resulted in a growing need for instituting policies and vector control activities to prevent further spread of infection. This is projected to fuel demand over the forecast period.
Hospitals are expected to be one of the fastest-growing segments owing to increasing awareness about preventive healthcare measures, including vaccination against infectious diseases, especially among high-risk groups such as pregnant women and AYUSH patients. Furthermore, introduction of advanced vaccines with improved efficacy is anticipated to boost market growth during future years. For instance, TAK-003 vaccine manufactured by Chugai Pharmaceutical Co., Ltd., which was approved by Japan¢â‚¬â„¢s Ministry Of Health In February 2016 is expected to gain significant demand from hospitals due its reduced dosage requirement (4 doses) as compared to other conventional tetravalent vaccines (8 doses).
Regional Analysis:
Asia Pacific dominated the global market in 2017 and is expected to continue its dominance over the forecast period. The presence of a large number of susceptible population, favorable climatic conditions for mosquito breeding, and increasing incidence of dengue are some factors responsible for this region’s largest share. Moreover, rising awareness about preventive measures taken against various diseases is anticipated to fuel demand in this region.
The Asia Pacific market was followed by Europe with a revenue share of around 25%. This can be attributed to high disease prevalence rates observed across countries such as Italy (35 cases per 100,000 people annually), Greece (27 cases per 100,000 people annually), and Spain (23 cases per 100,000 people annually). In addition there has been an increase in research studies conducted on dengue vaccines since they are considered promising candidates for future therapeutics against other flavivirus diseases such as West Nile Virus or Zika Virus Disease that pose a public health risk throughout the world.
Growth Factors:
- Increasing incidence of dengue fever across the globe
- Government initiatives for Dengue Vaccine development and distribution
- Growing public-private partnerships for vaccine development and commercialization
- Technological advancements in vaccine production and delivery mechanisms
- Rising awareness about dengue fever and its prevention
Scope Of The Report
Report Attributes
Report Details
Report Title
Dengue Vaccine Market Research Report
By Type
CYD-TDV, DENVax or TAK-003, TetraVax-DV, TDENV PIV, V180, DNA vaccines
By Application
Government Institutions, Hospitals, NGOs
By Companies
GlaxoSmithKline, Merck Sharp & Dohme, Sanofi, Takeda Pharmaceuticals, GeneOne Life Sciences, Medigen Biologics, Panacea Biotec, Sun Pharmaceutical, U.S NIH, Vabiotech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Dengue Vaccine Market Report Segments:
The global Dengue Vaccine market is segmented on the basis of:
Types
CYD-TDV, DENVax or TAK-003, TetraVax-DV, TDENV PIV, V180, DNA vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Government Institutions, Hospitals, NGOs
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Merck Sharp & Dohme
- Sanofi
- Takeda Pharmaceuticals
- GeneOne Life Sciences
- Medigen Biologics
- Panacea Biotec
- Sun Pharmaceutical
- U.S NIH
- Vabiotech
Highlights of The Dengue Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CYD-TDV
- DENVax or TAK-003
- TetraVax-DV
- TDENV PIV
- V180
- DNA vaccines
- By Application:
- Government Institutions
- Hospitals
- NGOs
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dengue Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dengue vaccine is a vaccine that helps prevent dengue fever. Dengue is a serious, sometimes deadly, viral illness caused by the dengue virus. There are four types of dengue: Asian, African, South American and Western equine. The Asian type is the most common in the United States. Symptoms include fever, headache and body aches; however, it can be more severe in some people. Aedes mosquitoes can spread the virus to humans through bites on skin or mucous membranes such as those of the nose or mouth. A vaccine against dengue has been available for many years but rates have not yet reached levels where it can be said to be effective in preventing disease outbreaks in populations at risk for infection (such as travelers). Ongoing research into this area may lead to improved vaccines and better protection against this mosquito-borne illness
Some of the major companies in the dengue vaccine market are GlaxoSmithKline, Merck Sharp & Dohme, Sanofi, Takeda Pharmaceuticals, GeneOne Life Sciences, Medigen Biologics, Panacea Biotec, Sun Pharmaceutical, U.S NIH, Vabiotech.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Dengue Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Dengue Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Dengue Vaccine Market - Supply Chain
4.5. Global Dengue Vaccine Market Forecast
4.5.1. Dengue Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Dengue Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Dengue Vaccine Market Absolute $ Opportunity
5. Global Dengue Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Dengue Vaccine Market Size and Volume Forecast by Type
5.3.1. CYD-TDV
5.3.2. DENVax or TAK-003
5.3.3. TetraVax-DV
5.3.4. TDENV PIV
5.3.5. V180
5.3.6. DNA vaccines
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Dengue Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Dengue Vaccine Market Size and Volume Forecast by Application
6.3.1. Government Institutions
6.3.2. Hospitals
6.3.3. NGOs
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Dengue Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Dengue Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Dengue Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Dengue Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Dengue Vaccine Demand Share Forecast, 2019-2026
9. North America Dengue Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Dengue Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Dengue Vaccine Market Size and Volume Forecast by Application
9.4.1. Government Institutions
9.4.2. Hospitals
9.4.3. NGOs
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Dengue Vaccine Market Size and Volume Forecast by Type
9.7.1. CYD-TDV
9.7.2. DENVax or TAK-003
9.7.3. TetraVax-DV
9.7.4. TDENV PIV
9.7.5. V180
9.7.6. DNA vaccines
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Dengue Vaccine Demand Share Forecast, 2019-2026
10. Latin America Dengue Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Dengue Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Dengue Vaccine Market Size and Volume Forecast by Application
10.4.1. Government Institutions
10.4.2. Hospitals
10.4.3. NGOs
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Dengue Vaccine Market Size and Volume Forecast by Type
10.7.1. CYD-TDV
10.7.2. DENVax or TAK-003
10.7.3. TetraVax-DV
10.7.4. TDENV PIV
10.7.5. V180
10.7.6. DNA vaccines
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Dengue Vaccine Demand Share Forecast, 2019-2026
11. Europe Dengue Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Dengue Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Dengue Vaccine Market Size and Volume Forecast by Application
11.4.1. Government Institutions
11.4.2. Hospitals
11.4.3. NGOs
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Dengue Vaccine Market Size and Volume Forecast by Type
11.7.1. CYD-TDV
11.7.2. DENVax or TAK-003
11.7.3. TetraVax-DV
11.7.4. TDENV PIV
11.7.5. V180
11.7.6. DNA vaccines
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Dengue Vaccine Demand Share, 2019-2026
12. Asia Pacific Dengue Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Dengue Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Dengue Vaccine Market Size and Volume Forecast by Application
12.4.1. Government Institutions
12.4.2. Hospitals
12.4.3. NGOs
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Dengue Vaccine Market Size and Volume Forecast by Type
12.7.1. CYD-TDV
12.7.2. DENVax or TAK-003
12.7.3. TetraVax-DV
12.7.4. TDENV PIV
12.7.5. V180
12.7.6. DNA vaccines
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Dengue Vaccine Demand Share, 2019-2026
13. Middle East & Africa Dengue Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Dengue Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Dengue Vaccine Market Size and Volume Forecast by Application
13.4.1. Government Institutions
13.4.2. Hospitals
13.4.3. NGOs
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Dengue Vaccine Market Size and Volume Forecast by Type
13.7.1. CYD-TDV
13.7.2. DENVax or TAK-003
13.7.3. TetraVax-DV
13.7.4. TDENV PIV
13.7.5. V180
13.7.6. DNA vaccines
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Dengue Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Dengue Vaccine Market: Market Share Analysis
14.2. Dengue Vaccine Distributors and Customers
14.3. Dengue Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck Sharp & Dohme
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Takeda Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GeneOne Life Sciences
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Medigen Biologics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Panacea Biotec
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sun Pharmaceutical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. U.S NIH
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Vabiotech
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
